DONALD W. WOODLEY, M.D.; WENDELL H. HALL, M.D., PH.D., F.A.C.P.
The efficacy of vancomycin (Vancocin®—Lilly) in the treatment of severe staphylococcal infections is becoming well established. According to several authors it is now the agent of choice if the organism is penicillin-resistant (1-3). Vancomycin has a bactericidal action for staphylococci, and as yet no resistant strains have been reported in clinical practice. Toxicity is often bothersome, but it is rarely serious or a cause for discontinuing therapy. A summary of our experience with this drug in 25 cases of serious staphylococcal infections will be presented, along with a review of the literature on vancomycin. The following cases are reported in
WOODLEY DW, HALL WH. The Treatment of Severe Staphylococcal Infections with Vancomycin. Ann Intern Med. ;55:235–249. doi: 10.7326/0003-4819-55-2-235
Download citation file:
Published: Ann Intern Med. 1961;55(2):235-249.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use